国际眼科纵览

• 综述 • 上一篇    下一篇

泪腺腺样囊性癌的临床治疗方式

柳睿 马建民   

  1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 眼科学与视觉科学北京市重点实验室 100730
  • 收稿日期:2019-10-10 出版日期:2019-12-22 发布日期:2019-12-26
  • 通讯作者: 马建民,Email:jmma@sina.com
  • 基金资助:

    北京市自然科学基金(7182038)

Treatment for adenoid cystic carcinoma of lacrimal gland

Liu Rui, Ma Jianmin   

  1. Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2019-10-10 Online:2019-12-22 Published:2019-12-26
  • Contact: Ma Jianmin, Email: jmma@sina.com
  • Supported by:

    Beijing Natural Science Foundation (7182038)

摘要:

泪腺腺样囊性癌是最常见的泪腺恶性上皮性肿瘤,发展迅速、易局部蔓延和远处转移,具有较高的复发率和死亡率。目前,临床治疗方式主要有手术切除联合粒子125I植入内放射治疗、手术切除联合外放射治疗、手术切除联合放化疗的综合应用,以及分子靶向药物治疗等。以上综合治疗方式对于降低患者的复发率、延长生存期具有一定的效果。同时需要关注放射治疗和化学疗法的副作用。(国际眼科纵览,2019, 43: 415-420)

Abstract:

Adenoid cystic carcinoma of the lacrimal gland is the most common malignant epithelial neoplasm of the lacrimal glands. It develops rapidly, spreads locally and metastases distantly. It has a high recurrence rate and mortality rate. At present, the main clinical treatment methods are surgical resection combined with particle 125I implantation and internal radiotherapy, surgical resection combined with external radiotherapy, surgical resection combined with radiotherapy and chemotherapy, and molecular targeted drug therapy, etc. The above comprehensive treatments has reduced the recurrence rate and prolonged the survival span of patients. At the same time we need to keep in mind the side effects of radiotherapy and chemotherapy.(Int Rev Ophthalmol, 2019, 43: 415-420)